Genocea Biosciences (NASDAQ:GNCA) Getting Somewhat Positive News Coverage, Analysis Finds
Press coverage about Genocea Biosciences (NASDAQ:GNCA) has trended somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Genocea Biosciences earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 100 out of 100, meaning that recent news coverage is extremely likely to have an impact on the company’s share price in the immediate future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Investor Update: Company Share Focus for Genocea Biosciences, Inc. (NASDAQ:GNCA) – Jonesboro Recorder (jonesbororecorder.com)
- Genocea Biosciences, Inc. (GNCA) Expected to Post Earnings of -$0.46 Per Share (americanbankingnews.com)
- Genocea Biosciences, Inc. (GNCA) noted a price change of -2.02% and Protagonist Therapeutics, Inc. (PTGX) closes … – Stocks Gallery (stocksgallery.com)
- Genocea Biosciences, Inc. (GNCA) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
Shares of Genocea Biosciences (NASDAQ:GNCA) traded up 1.02% during midday trading on Friday, hitting $4.94. The company had a trading volume of 101,607 shares. The stock’s market capitalization is $140.81 million. The stock’s 50-day moving average price is $5.76 and its 200-day moving average price is $5.35. Genocea Biosciences has a one year low of $3.28 and a one year high of $7.29.
Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.06. Analysts predict that Genocea Biosciences will post ($1.89) EPS for the current year.
Separately, Zacks Investment Research downgraded Genocea Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, June 5th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Genocea Biosciences presently has an average rating of “Buy” and an average price target of $16.02.
ILLEGAL ACTIVITY NOTICE: This news story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/07/16/genocea-biosciences-gnca-earns-daily-news-sentiment-score-of-0-16-updated-updated-updated.html.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.